Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease
- Conditions
- Hemophilia
- Registration Number
- NCT04282486
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
The improvements observed in the care of patients with hemophilia or Willebrand disease have led to an increase in their life expectancy, which today approaches that of the general population. This increase in life expectancy leads in these patients to the development of comorbidities related to aging (cardiovascular and neurological diseases, cancers and kidney diseases) (e.g "Franchini \& Mannuccio", BJH, 2009). The care of these comorbidities represents a new challenge for the medical teams. Toward multiple comorbidities, polypharmacy is often associated.
Many studies about medication exposure and management in older patients were published but no study was conducted to explore the medication management of older patients with hemophilia or Willebrand disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 142
- Community-dwelling patients over 65 years with hemophilia (A or B)
- Community-dwelling patients over 65 years with Willebrand disease (Type1, 2 and 3, rate <30%)
- Patients without phone number
- Non French speaking patients
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Potentially inappropriate medication (PIM) prevalence using EU-(7) PIM list. At inclusion A telephone interview will be conducted with patients in order to collect medication data from medical prescriptions. After collection of data for all patients, the research of PIM was conducted.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hôpital des Charpennes, Institut du Vieillissement
🇫🇷Villeurbanne, France